FDA Proposes Excluding Semaglutide and Tirzepatide from 503B Compounding List
The FDA proposed removing semaglutide and tirzepatide from the 503B compounding list, which would prevent outsourcing facilities from mass-producing unapproved versions. Public comments accepted through June 29, 2026.
What This Means for You
The FDA proposed removing semaglutide and tirzepatide from the 503B compounding list, which would prevent outsourcing facilities from mass-producing unapproved versions. Public comments accepted through June 29, 2026.
On April 30, 2026, the FDA moved to strip semaglutide and tirzepatide from the list of bulk drug substances that 503B outsourcing facilities can compound. The proposal follows the official resolution of shortages for both drugs in late 2024 and early 2025, respectively.
503B facilities have been a key source of cheaper compounded GLP-1s — often $199–$349 per month versus $850–$1,350 retail for branded versions. Removing these ingredients from the 503B list would force those facilities to stop producing them. The 503A compounding pharmacies (traditional retail pharmacies) could still dispense some compounded versions, but only if they meet stricter patient-specific clinical-need requirements.
Eli Lilly issued a press release welcoming the proposal, stating it would “protect patients from unregulated, unsafe compounded products.” Novo Nordisk also endorsed the move. Critics argue that many patients rely on compounded GLP-1s because insurance doesn’t cover branded versions, and removing the 503B pathway will push costs up sharply.
Public comment on the proposal runs through June 29, 2026. The FDA has not set a timeline for a final rule, but the direction is clear: the era of widely available compounded semaglutide and tirzepatide through 503B facilities is likely ending.
Frequently Asked Questions
What does this mean for my compounded semaglutide prescription?
If you currently get compounded semaglutide from a 503B outsourcing facility, there is no immediate change. The FDA is in a 60-day comment period. However, you should discuss alternatives with your provider — either switching to a 503A pharmacy (which may have stricter limits) or exploring brand-name options with savings cards.
Are 503A pharmacies affected by this proposal?
Not directly. 503A pharmacies compound patient-specific prescriptions and are subject to different rules. However, the FDA is also reviewing whether compounded GLP-1s that are “essentially copies” of approved drugs can continue under any compounding framework.
When will this take effect?
The comment period closes June 29, 2026. The FDA typically takes several months to review comments and issue a final rule. Realistically, enforcement could begin in late 2026 or early 2027.
Source: Reuters
Frequently Asked Questions
What does this mean for my compounded semaglutide prescription?
Are 503A pharmacies affected by this proposal?
When will this take effect?
Original source
Read the full article at Reuters